Loading stock data…
DiaMedica Therapeutics Inc (DMAC)
$7.22+0.67 (+10.23%)
After Hours$7.22+0.00 (+0.00%)· Last close Jun 29
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DiaMedica Therapeutics Inc. in the Healthcare sector is trading at $7.22 with a market capitalization of $293M. Wall Street consensus targets $15.50 (4 analysts), implying a +114.7% move over the next 12 months. The stock is currently 31% below its 52-week high of $10.42, remaining 0.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +114.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.48M↓ | -$9.21M↓ | -$9.03M↓ | -$8.01M↑ | -$8.14M |
| Net Income | -$10.04M↓ | -$8.74M↓ | -$8.62M↓ | -$7.70M↑ | -$7.71M |
Peer Comparison
JNJUNHPFE
Fundamentals
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$292.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-74.31%
Volume
Today's trading volume
386,008
Recent News
DiaMedica (DMAC) Q4 2025 Earnings Transcript
Need a quote from a Motley Fool analyst? Dietrich Pauls: Thank you, Morgan, and thank you all for joining us for our fiscal year 2025 earnings call. With me this morning are Dr. Julie Krop, our Chief Medical Officer; and Scott Kellen, our Chief Financial Officer.
DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
DiaMedica Therapeutics Q1 Earnings Call Highlights
DiaMedica Therapeutics (NASDAQ:DMAC) executives outlined progress across the company’s DM199 clinical programs in preeclampsia and acute ischemic stroke during the company’s first-quarter 2026 earnings call, while also reviewing quarter-end liquidity and spending trends as development work expands g
DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference
DiaMedica Therapeutics (NASDAQ:DMAC) President and CEO Rick Pauls outlined the company’s development programs for its lead candidate, DM199, during a presentation at the RedChip Biotech Investor Conference, highlighting ongoing work in preeclampsia and acute ischemic stroke as well as upcoming clini
DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...
DiaMedica Therapeutics Inc (DMAC) reports robust financial health and significant advancements in its clinical trials, despite facing some enrollment and regulatory challenges.